The fund is the result of a collaboration between the Spanish fund manager Trea AM and Discovery Ventures, which specialises in life sciences and has experience investing in successful companies such as Quethera, Orchard Therapeutics and Gensight.
The new investment vehicle falls under Article 9 of the European SFDR for its positive social impact and is aimed at investing in biotechnology companies, medical devices or applied health technologies that develop new techniques such as gene therapy, advanced cell therapy, nano-biotechnology, bionics, tissue engineering and artificial intelligence.
The KWM team of lawyers involved in this project has been led by partner and head of the funds department Isabel Rodríguez, together with associates Enrique Torné and Lara Taylor.
